|Articles|April 3, 2003

FDA Reclassifies Knee Joints

WASHINGTON -- The Food and Drug Administration (FDA) has reclassified two fixed-bearing knee joint prostheses, the patellofemorotibial and the femorotibial (uni-compartmental) metal/polymer porous-coated uncemented prosthesis, from class III devices (i.e., premarket approval) to class II devices (i.e., special controls).

The special control that will apply to the patellofemorotibial prosthesis, used for whole knee joint replacement, and the femorotibial prosthesis, used for partial knee joint replacement, is titled "Class II Special Controls Guidance Document: Knee Joint Patellofemorotibial and Femorotibial Metal/Polymer Porous-coated Uncemented Prostheses; Guidance for Industry and FDA."

The FDA reasoned that special controls, in addition to general controls, will provide reasonable assurance of the safety and effectiveness of the devices. The rule was effective March 24, 2003. For more information, visit http://www.fda.gov/OHRMS/DOCKETS/98fr/ 03-6857.html.


Related to this article

Water  (Adobe Stock 456102510 by stockphoto-graf)
Understanding current water quality is a starting point for ST108 implementation. John Kimsey, vice president of processing optimization and customer success for STERISS, spoke about his HSPA presentation on assessing readiness, distinguishing system qualification from routine testing, and understanding where water samples should be collected.
Image of Pathogens flying   (Adobe Stock weerasak)
Behind every landmark in infection prevention, from antimicrobial stewardship guidelines to the COVID-19 town halls that reached flight attendants and teachers, is a generation of physician-scientists who led SHEA through crises, organizational change, and scientific breakthroughs. Infection Control Today traces 30 years of SHEA presidents and the lasting mark they left on the field.
AORN26 New Orleans 2026  (Adobe Stock)
Missing instruments and processing delays can strain OR–SPD relationships. At AORN 2026, John Kimsey, vice president of processing optimization and customer success for STERIS, discusses understanding root causes, exploring off-site reprocessing for ambulatory surgical centers, and using hands-on simulation to help surgical teams see sterile processing from a different perspective.